Agios Pharmaceuticals, Inc.
AGIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.0B
$33.10
▼ -0.09%
P/E
-4.72
Mkt Cap
$2.0B
52-Wk Range
$22.24–$46.00
52-Week Range
$22.24 - $46.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 9.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- First-in-class PYRUKYND (mitapivat) with FDA approval and market exclusivity
- Proprietary expertise in cellular metabolism and enzyme activation mechanisms
- Strong intellectual property portfolio protecting novel drug targets and formulations
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Strong growth ahead
PYRUKYND commercial expansion and market penetration in hemolytic anemias
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+20.6% over 3m
Quality
Excellent
Emerging growth company (141% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying AGIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of -$1.69 vs -$1.65 consensus (-2.4% surprise). Revenue of $44.7M vs $26.4M expected (+69.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.4%
Revenue trend · last 8Q
—
+51%
+7%
+45%
+44%
+86%
+138%
+259%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$9.0M
$10.7M
$8.7M
$12.5M
$12.9M
$20.0M
$20.7M
$44.7M
Margins · last 8Q
Gross
93.3%
Profit
-225.1%
Wall Street consensus
7 analysts · 57% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
57%
Hold
43%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 31, 2026
vs Industry
How AGIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related